College of American Pathologists
CAP Committees & Leadership CAP Calendar of Events Estore CAP Media Center CAP Foundation
About CAP    Career Center    Contact Us      
Search: Search
  [Advanced Search]  
CAP Home CAP Advocacy CAP Reference Resources and Publications CAP Education Programs CAP Accreditation and Laboratory Improvement CAP Members
CAP Home > CAP Calendar of Events > Webinars

Featured Sessions

Upcoming Sessions   Previous Sessions  
Member Meeting Calendar
Membership login required

   LOG IN >


Economics 101:
In-house vs. Reference Testing: Criteria to Consider for Molecular Testing

In today's challenging healthcare environment the search for the most value out of our diagnostic tests is becoming more and more prominent. There are clearly more tests available than any single laboratory could run. As a result, pathologists and medical directors frequently must answer the question "Should I offer this test, or send it to a reference laboratory?"

The purpose of this webinar is to address this challenging question and systematically review the numerous components in this decision making process. Specifically, this talk will provide the tools to address the following six areas:

 • Medical Management Value
 • Current Status of Testing
 • Stakeholder Analysis
 • Instrumentation Analysis
 • Financial Analysis
 • SWOT (Strengths, Weaknesses, Opportunities, Threats)

This webinar is designed to of educational value to both the early career pathologist to experienced medical directors. At the end of this presentation, the participants should be able to:

 1. Define the key components in the decision to either perform a test in
     house or send it to a reference lab
 2. Perform and identify the value in performing a stakeholder analysis, and
     how it can be utilized to effectively communicate about the service
 3. Employ key financial concepts to compose a break even analysis of a
     particular service
 4. Perform a SWOT analysis as a defined tool to "scan the horizon" for
     influencing factors

Jordan S. Laser, MD, FCAP

Oct 22, 2014
11-12 pm PM CT

Register Now

Ex vivo pathology applications of IVM:
Cooler than Frozen

Ex vivo microscopy (EVM) involves the rapid imaging of biopsy material without requiring traditional fixation, sectioning and staining. A number of emerging technologies exist, including rapid confocal and wide-field optical coherence tomography. Potential applications of EVM include replacement of conventional frozen sections for surgical margin evaluation, including adequacy assessment of excisional biopsies. It can also be used to triage which specimens may be sent for traditional histology, and for assurance that specimens submitted for molecular profiling contain sufficient appropriate material. Down the road, the quality of the imaging may allow for definitive primary diagnosis, speeding up the workflow of patient evaluation. New technologies for rapid staining (immunofluorescence or FISH) may also allow same-day molecular phenotyping.

Since pathologists are expert at interpreting microscopic images, it is important that pathology as a field plays a role in how these technologies will be used. In this talk, I will review the key, commercially available EVM technologies and discuss the implications for pathology involvement and workflow.

Richard M. Levenson, MD, FCAP

Oct 23, 2014
11-12 PM CT

Register Now


Breast Predictive Factors:
Resolving Test Interpretation Challenges

This interactive case-based webinar worth 1.5 CME, will answer your common questions and challenges related to HER2 and ER/PgR testing. Two of the ASCO/CAP Guideline authors will facilitate a tumor board-like experience where participants weigh-in on real patient cases. This is a unique opportunity to come together and learn from the experts and other pathologists doing breast predictive factors testing.

As a result of participating in this education activity, you will be able to:

 • Accurately interpret HER2 tests as positive, negative or equivocal
    according to the ASCO/CAP HER2 Guideline criteria.
 • Evaluate and integrate HER2 test results with clinical
    and morphologic findings.
 • Determine appropriate next steps when a HER2 test result
    is discordant with the patient’s profile or other HER2 tests.
 • Apply the ASCO/CAP Guideline criteria for reporting
    HER2 test results.
 • Provide appropriate resolution and clarification in reports
    when HER2 results are equivocal, indeterminate,
    or complex (eg, intratumoral heterogeneity
    or chromosome 17 aneusomy).

Dr. M. Elizabeth Hammond
Dr. David Hicks

Nov. 6, 2014
12-1:30 PM CT

Register Now

Practical Genomics for the Practicing Pathologist Webinar Series – Selecting the Right Tissue for Genomic Oncology Testing

This CME webinar will specify the criteria for determining if cells of diagnostic interest are present in a specimen in sufficient quantities for oncology genomic testing. It will include information on developing a quality management program to ensure appropriate specimen collection through slide review and techniques for providing feedback to clinicians regarding specimen quality.


    1. Assess and document tumor cell percent.
    2. Describe the impact of overestimating or underestimating
        tumor cell percentage with regard to molecular testing.
    3. Identify tissue suitable for genomic testing.

Dr. Sophia Yohe, MD, FCAP

Nov. 20, 2014
12:00 PM - 1:00PM CT

Register Now
 © 2014 College of American Pathologists. All rights reserved. | Terms and Conditions | CAP ConnectFollow Us on FacebookFollow Us on LinkedInFollow Us on TwitterFollow Us on YouTubeFollow Us on FlickrSubscribe to a CAP RSS Feed